Dexcom outperforms growth expectations but proceeds with caution

Dexcom started out the year strong following the FDA clearance of its integrated continuous glucose monitor the G6. In its Q1 earnings call, the company reported a 30 percent increase in revenue compared to Q1 of 2017, bringing its total revenue to $184 million. When the FDA gave Dexcom the nod for the G6 it became the first interoperable CGM to get the designation. According to the earnings call, the technology is set for a full launch by June. 

from MobiHealthNews https://ift.tt/2INiQK3